347 related articles for article (PubMed ID: 21626603)
1. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
2. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
3. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
Leoni V; Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263255
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
8. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
Menotti L; Nicoletti G; Gatta V; Croci S; Landuzzi L; De Giovanni C; Nanni P; Lollini PL; Campadelli-Fiume G
Proc Natl Acad Sci U S A; 2009 Jun; 106(22):9039-44. PubMed ID: 19458262
[TBL] [Abstract][Full Text] [Related]
10. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
13. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
14. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
15. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
Campadelli-Fiume G; Petrovic B; Leoni V; Gianni T; Avitabile E; Casiraghi C; Gatta V
Viruses; 2016 Feb; 8(3):63. PubMed ID: 26927159
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
17. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
18. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
19. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of herpesviruses as oncolytic agents.
Menotti L; Campadelli-Fiume G; Nanni P; Lollini PL; De Giovanni C
Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
